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Abstract
Numerous experimental vaccines have been developed to protect against the cutaneous and visceral forms of leishmaniasis
caused by infection with the obligate intracellular protozoan Leishmania, but a human vaccine still does not exist.
Remarkably, the efficacy of anti-Leishmania vaccines has never been fully evaluated under experimental conditions
following natural vector transmission by infected sand fly bite. The only immunization strategy known to protect humans
against natural exposure is ‘‘leishmanization,’’ in which viable L. major parasites are intentionally inoculated into a selected
site in the skin. We employed mice with healed L. major infections to mimic leishmanization, and found tissue-seeking,
cytokine-producing CD4+ T cells specific for Leishmania at the site of challenge by infected sand fly bite within 24 hours,
and these mice were highly resistant to sand fly transmitted infection. In contrast, mice vaccinated with a killed vaccine
comprised of autoclaved L. major antigen (ALM)+CpG oligodeoxynucleotides that protected against needle inoculation of
parasites, showed delayed expression of protective immunity and failed to protect against infected sand fly challenge. Two-
photon intra-vital microscopy and flow cytometric analysis revealed that sand fly, but not needle challenge, resulted in the
maintenance of a localized neutrophilic response at the inoculation site, and removal of neutrophils following vector
transmission led to increased parasite-specific immune responses and promoted the efficacy of the killed vaccine. These
observations identify the critical immunological factors influencing vaccine efficacy following natural transmission of
Leishmania.
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Introduction
Leishmania are obligate-intracellular protozoan parasites that
establish infection in mammalian hosts following transmission to
the skin by the bite of an infected Phlebotomine sand fly [1].
Different Leishmania species are associated with a spectrum of
clinical outcomes in humans, including fatal, disseminated
infection of the spleen and liver following infection with L.
donovani, and self-curing cutaneous lesions associated with L. major
and other cutaneous strains. Healed cutaneous lesions often result
in a permanent scar that has been shown to harbor low numbers
of parasites over the long term [2]. While this chronic, sub-clinical
state can serve as a long-term reservoir for disease, it also
maintains powerful protective immunity for the host, as individuals
with healed primary lesions are highly resistant to re-infection, and
complete elimination of a primary infection in animal models
results in susceptibility to reinfection [3,4]. Deliberate needle
inoculation with viable parasites in a selected site, referred to as
‘‘leishmanization,’’ has been employed extensively as a live
‘‘vaccine’’ in people for generations, and is highly effective against
natural exposure [5,6,7,8]. However, due to reports of adverse
reactions at the site of inoculation, quality control issues, and
concerns over causing serious disease in immuno-compromised
individuals, leishmanization has fallen out of favor [8,9].
Employing the mouse model of L. major infection, numerous
non-living [10,11,12,13,14,15] and live-attenuated [13,16,17], or
DNA-based [10,18] vaccine formulations have been developed as
alternatives to leishmanization, which in many cases have
conferred relatively long-term protection against experimental
needle challenge [10,11,12,18]. In contrast, non-living vaccines,
including formulations similar to those shown to work effectively in
mice against needle challenge [11,13], have yet to confer
significant protection against natural exposure in people, despite
the generation of measurable cell-mediated immunity
[9,19,20,21,22,23,24,25,26,27,28]. This contradiction between
the results in humans and animal trials suggests that the correlates
of vaccine efficacy developed mainly from the mouse model,
namely the generation of Th1 responses and the reduction of
lesion size and/or parasite number following needle challenge,
may not adequately define the requirements for protection against
natural transmission. Observations by Rogers et al. [29], in which
vaccination with soluble leishmanial antigen plus IL-12 delayed
the onset of progressive lesions following needle, but not infected
sand fly challenge in BALB/c mice, support this suggestion.
In addition to the delivery of infectious stage parasites into the
dermis, sand flies also deposit pharmacologically active saliva,
which aids in blood feeding, and egest parasite-released glycocon-
jugates, which accumulate behind the mouthparts in infected flies
and form a promastigote secretory gel (PSG). These molecules
have been shown to enhance the severity of disease when co-
administered with infectious stage parasites [30,31,32,33]. We
have recently reported that sand fly transmission induces a
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site that includes a dynamic recruitment of neutrophils, and that
these neutrophils markedly enhance the ability of parasites to
establish primary infection [34]. Thus, an analysis of the influence
of sand fly transmission on vaccine efficacy is likely to be highly
relevant to the generation of a Leishmania vaccine that is effective in
people.
Results
Healed primary infection protects against infected sand
fly challenge
Healed primary L. major infection initiated by needle inoculation
of mice has been extensively employed as a model that mimics the
clinical practice of leishmanization. Mice with resolved primary
lesions harbor L. major specific CD4 T cells that simultaneously
produce IFN-c, TNF-a, and IL-2 effector cytokines and mount
powerful protective immunity at a site of needle re-challenge,
resulting in the rapid control of parasite growth [13,35]. In order
to characterize the protective immune response following natural
transmission, 4 P. duboscqi sand flies, infected with L. major (L.m.-
SF), were allowed to feed on the ears of C57BL/6 mice with a
healed primary lesion in the footpad. Under these conditions, a
median of 2 flies will show evidence of blood engorgement,
thereby ensuring parasite transmission to a sufficient number of
ears to conduct the experiment, while at the same time more
faithfully replicating natural transmission, which likely occurs
following exposure to a single infected fly. At 1 and 3 days
following exposure to the infected flies, a slight but significant
increase in infiltrating CD4 T cells was found in the ears of healed
mice relative to fly challenged, naı ¨ve, age-matched controls (AMC)
(Figure 1A). At 7 days post-challenge, the number of infiltrating
CD4 cells in the healed mice was dramatically increased relative to
controls. In order to determine if parasite antigen was required to
mediate this recruitment, healed mice were also exposed to
uninfected sand fly bites (SF). Both infected or uninfected bites
recruited equivalent numbers of T cells at day 3 post-bite,
however, parasite antigen appeared necessary for the dramatic
increase observed on day 7 (Figure 1A). Remarkably, Ag re-
stimulation of dermal derived cells revealed Leishmania-specific
IFN-c producing CD4+ T cells at the challenge site within
24 hours, a response that gradually increased to 17% of the total
CD4 T cell population at 7 days (Figure 1B), correlating with a
.100 fold reduction in parasite numbers in the skin (Figure 1C).
Antigen re-stimulation of T cells from the ears of healed mice
exposed to uninfected sand fly bites also revealed the presence of
L.m.-specific IFN-c producing CD4+ T cells (Figure 1B),
suggesting that a functional property of these effector cells is their
ability to rapidly migrate to sites of tissue inflammation whether
antigen is present or not.
ALM+CpG vaccination fails to protect against infected
sand fly challenge
Vaccination with autoclaved L. major (ALM), or a recombinant
leishmania protein, plus CpG oligodeoxynucleotides (ODN) has
been shown to effectively protect against needle challenge with L.
major in mice [11,13]. We therefore employed ALM+CpG to test
the efficacy of a non-living vaccine against natural transmission.
Mice vaccinated with ALM+CpG three times s.c. in the footpad at
two week intervals, along with age-matched naı ¨ve controls and
mice with healed primary lesions, were exposed to the bites of 4
infected sand flies twelve weeks following the last vaccine injection.
Four weeks following infected sand fly exposure or needle
inoculation, coincident with the time of peak parasitic load in
naı ¨ve mice, parasite burden in the ear dermis was assessed. Mice
with healed primary lesions again dramatically controlled parasite
growth following exposure to the bites of infected sand flies
(Figure 2A). In contrast, ALM+CpG vaccination conferred no
protection against transmission by sand fly bite, despite conferring
strong protection against needle inoculation. Ear lesion measure-
ments obtained 4 weeks after infection also revealed a compro-
mised benefit of the ALM+CpG vaccine against sand fly challenge
(Figure S1). Note that despite the comparable parasitic loads in
naı ¨ve mice following sand fly or needle challenge, the pathology
associated with transmission by bite was far more severe.
The respective doses of the fly versus needle inocula did not
appear to be a factor in the different outcomes of infection in the
ALM+CpG vaccine as naive mice infected via needle or sand fly
bite contained similar numbers of parasites in the challenge sites at
4 wks post-infection. In order to address the issue of dose more
directly, and to determine if sand fly-derived parasites might be
more virulent than those obtained from culture, ALM+CpG
vaccinated and healed mice were challenged by infected sand fly
bite or by inoculation with a five-fold higher dose of metacyclic
promastigotes purified from the midguts of sand flies harboring
14 d, mature infections. Based on previous observations [36],
5610
3 sand fly derived parasites are within the projected upper
range of the variable doses transmitted following exposure to 4
infected sand flies. Mice with healed primary lesions were again
powerfully protected against both needle and sand fly challenge
(Figure 2B), and the ALM+CpG vaccinated mice maintained
their immunity against the higher dose, sand fly-derived, needle
inoculum, demonstrating a 100-fold decrease in parasite load.
Importantly, these mice again failed to demonstrate any protection
against sand fly transmitted infection as measured by either
parasite load (Figure 2B), or a significant reduction in lesion
scores (Figure S2). These results strongly suggest that transmis-
sion of L. major by sand fly bite, rather than an inherent difference
in the dose or virulence of sand fly derived parasites, is responsible
for the inability of ALM+CpG vaccinated mice to protect against
natural challenge.
Kinetic analysis of the immune response among groups of mice
challenged by the bite of infected sand flies in Figure 2A revealed
that healed mice mounted a rapid and robust L.m.-specific
response, while ALM+CpG vaccinated mice mounted a much
Author Summary
The generation of vaccines that protect against intracel-
lular pathogens such as malaria, human immunodeficiency
virus and leishmaniasis have met with limited success. A
perplexing aspect of this failure as it relates to leishman-
iasis is the knowledge that individuals typically get the
disease only once, and that individuals who are experi-
mentally infected with cultured parasites are protected
against sand fly transmitted infection, thereby providing a
‘‘gold standard’’ for vaccine design. Many engineered, non-
living vaccines have been developed to mimic the immune
response observed in protected individuals and some of
these have been shown to provide excellent protection
against needle inoculation of Leishmania parasites in mice.
However, very similar vaccine formulations adapted for use
in people have failed to protect against natural exposure
to infected sand fly bites. In the present study, we attempt
to reconcile these long-standing differences, and to
provide the critical correlates of immunity that will predict
vaccination success against natural exposure.
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dermal- derived CD3
+ T cells for IFN-c (Figure 2C) or TNF-a
(Figure 2D). These different effector cell frequencies were
reflected in the levels of IFN-c secreted by ear-derived cells, as
detected by ELISA (Figure 2E). Previous observations suggest
that CD4+ T cells capable of producing multiple cytokines in
response to antigen stimulation are more effective at protecting
against disease [13]. In agreement with these studies, we found
that a large proportion of L.m.-specific T cells in the healed mice
produced IFN-c and TNF-a simultaneously at day 7 (Figure 2F).
These results emphasize the correlation between an early response
and parasite clearance following sand fly transmission, and explain
why ALM+CpG vaccinated mice were unable to control sand fly
transmitted infection as compared to healed mice.
We were also interested to understand why the delayed
appearance of the Th1 effector response in ALM+CpG vaccinated
mice was sufficient to protect against needle challenge but not sand
fly challenge. At 4 wks post-infection, despite enhanced numbers
of lymphocytes (Figure S3) and increased levels of parasite
antigen (Figure 2A) at the site of infected sand fly bite versus
needle inoculation in ALM+CpG vaccinated mice, we observed a
decrease in the frequency of both IFN-c
+ (6.8% versus 11%) and
TNF-a
+ (3.7% versus 9.3%) L.m.-specific T cells (Figure 2, C
and D), as well as reduced levels of secreted IFN-c (Figure 2E).
Thus, conditions in the bite site appear to compromise the
activation and/or effector function of the memory response
generated by the killed vaccine.
Sand fly inoculation maintains a localized neutrophilic
response
We have recently demonstrated that the early host response to
sand fly bites is associated with a unique and prolonged
recruitment of neutrophils into the localized bite site, resulting in
the formation of a ‘‘neutrophil plug’’, and that the presence of
neutrophils during the initiation of infection promotes the
establishment of sand fly transmitted disease [34]. In order to
explore the possibility that the host inflammatory response to sand
fly bite is responsible for the failure of ALM+CpG vaccination to
protect against sand fly transmitted infection, we first compared
the inflammation induced by sand fly versus needle inoculation of
Figure 1. Mice with healed primary infections mount robust immunity and control parasite growth following transmission of L.
major by infected sand fly bite. Ears of naı ¨ve, age matched control mice (AMC), or healed mice infected by needle inoculation s.c. in the footpad
with 10
4 L.m. metacyclic promastigotes 22 weeks previously, were exposed to the bites of 4 uninfected (SF) or L.m.-infected P. duboscqi sand flies
(L.m.-SF). Ear derived cells were analyzed at the indicated times following exposure to sand flies. (A and B) Total number of TcRb
+CD4
+ T cells per ear
as determined by flow cytometric analysis of duplicate samples of pooled ears (A); or frequency (total number per ear in brackets) of IFN-c
+/
TcRb
+CD4
+ T cells following in-vitro re-stimulation of pooled ears with BMDC plus L. major-antigen (DC+Ag) (B). (*) or ({) in 1A indicates a significant
difference (0.021,p,0.034) between the number of cells per ear in Healed (L.m.-SF) or Healed (SF) versus AMC mice, respectively. (C) Parasite loads
in individual ears (circles) or ear DLNs (squares) one week following exposure to infected sand fly bites in AMC and healed animals, (*) p=0.007.
doi:10.1371/journal.ppat.1000484.g001
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ALM+CpG vaccinated mice (Figure 3B) were analyzed for the
presence of neutrophils over the first week of infection, both needle
and sand fly inoculated ears revealed a significant recruitment at
24 hours, although sand fly bitten ears had significantly greater
numbers (p=0.001). Importantly, only sand fly bitten ears
maintained the neutrophilic infiltrate at the inoculation site at 3
and 8 days post-inoculation (Figure 3, A and B). Of note, a very
transient neutrophilic response was also observed in the ears of the
sham-transmitted mice, elicited by manipulation of the ear dermis
during exposure to the transmission apparatus. Examination of
cells derived from the ears of the needle or sand fly challenged
mice shown in Figure 2A, revealed that only sand fly inoculation
maintained recruitment of large numbers of neutrophils at the
inoculation site at 1 and even 4 wks post-infection (Figure 3, C
and D), which at least in the case of the naı ¨ve mice, was not
explained by differences in the parasitic load. Analysis of all
CD11b and Ly-6G/C (Gr-1) expressing cells reveals that increased
numbers of neutrophils were also associated with large numbers of
CD11b+Gr-1
int macrophages/monocytes (Figure 3E).
In order to visualize neutrophil recruitment and maintenance at
individual sites of L.m. inoculation over time, we employed 2-
photon intra-vital microscopy (2P-IVM) in conjunction with a red
fluorescent protein-expressing strain of L.m (L.m.-RFP) [36], and
naı ¨ve mice expressing enhanced green fluorescent protein (eGFP)
under the control of the endogenous lysozyme M promotor (LYS-
eGFP mice) [37]. As previously reported, the GFP
hi cells in these
mice are neutrophils [34,37], and accumulate within both needle
and sand fly inoculation sites shortly after infection (Figure 3F,
2 hours; and Video S1 and S2). The sand fly inoculation site is
distinguished by an especially tight co-localization of RFP
+
parasites and GFP
hi neutrophils, which form a plug delineating
the site of proboscis penetration. (Figure 3F, 2 hours; Video S1
and S3). While neutrophils were maintained at the site of parasite
deposition by sand fly bite (Figure 3F, Video S4) this co-
localization was rapidly lost at the site of needle inoculation, and
the majority of neutrophils present in the field of view at later
times were within blood vessels (Figure 3F and Video S5).
Immunity is enhanced in the absence of neutrophils
We explored the possibility that neutrophil depletion might
rescue the ability of the killed vaccine to confer protection against
sand fly transmitted infection. As neutrophils are important for the
early establishment of sand flytransmitted infections, theirdepletion
at the time of challenge would, as previously shown [34], promote
early resistance and compromise infection even in the naı ¨ve mice.
Thus, the mice were left untreated for the first 3.5 days following
sand fly transmission, then treated on days 3.5, 9, and 14, with a
neutrophil depleting Ab [38,39] or control IgG to mimic the loss of
neutrophils observed following needle inoculation, but not sand fly
transmission. Analysis of CD11b
+Ly-6G
+F4/80
2 neutrophils and
CD11b
+Ly-6G
2F4/80
+ macrophages/monocytes at the site of
infection 6 days post-transmission revealed that the neutrophil
depletion was both specific and efficient (Figure 4, A and B). At 2
weeks post-transmission, the neutrophil depletion promoted
stronger Ag-specific IFN-c and TNF-a responses in the ALM+CpG
vaccinated mice (Figure 4C). More importantly, the neutrophil
depletion enhanced the efficacy of the killed vaccine. Analysis of
extensive data pooled from three independent experiments revealed
that on day 28 post-transmission, the neutrophil depleted,
ALM+CpG-vaccinated mice showed a highly significant reduction
in parasite load compared with neutrophil depleted, naı ¨ve mice
(p,0.0001), as well as control treated, ALM+CpG vaccinated mice
(p=0.002), and indistinguishable from that in healed animals
(Figure 4D). The enhanced parasite clearance in neutrophil
depleted, ALM+CpG vaccinated mice was associated with a
significant reduction in lesion size compared with neutrophil
depleted, naı ¨ve mice (p,0.0001) and control treated, ALM+CpG
vaccinated mice (p=0.01) (Figure 4E). Importantly, the neutro-
phil-depleted, naı ¨ve controls did not exhibit lower parasite loads
compared with their control treated counterparts, suggesting the
effect of neutrophil depletion after the initial establishment of
infection, and during the extended period of neutrophil recruitment
following transmission by bite, was specific to the vaccine setting.
Discussion
The generation of a safe, non-living, prophylactic vaccine
against leishmaniasis has been largely unsuccessful, a failure that is
not explained by the lack of available target antigens with the
potential to confer a protective response [40]. Failed human trials
reported in the 1990s employing ALM+BCG were particularly
perplexing as the same or a similar vaccine has been shown to
work well as immunotherapy to hasten cure in patients with active
disease [41,42]. Furthermore, it elicits detectable parasite-specific
IFN-c production and leishmanin skin-test conversion in at least a
proportion of recipients [20,21,22,23,24,25,26,27,28], and similar
vaccine formulations, including the ALM+CpG vaccine employed
in this study, have been shown to be highly effective against needle
challenge in mouse models [11,13]. The results reported here
suggest that the killed vaccines failed in people because, while
generating some correlates of immunity that may provide
adequate defense against a needle inoculum, failed to generate
and/or maintain the rapid, robust response at the site of secondary
challenge induced by leishmanization that is required to prevent
disease following delivery of parasites by sand fly bite. The
protective response in healed mice is likely associated with the
speed with which effector cells appear at a site of tissue damage,
irrespective of the presence of parasites (see Figure 1). Following
encounter with antigen in the inoculation site, these cells might
then provide an immediate burst of effector cytokines, and
counteract early on the down-modulatory environment created by
the highly localized, neutrophil-dominated, response to sand fly
bite. In contrast, and despite the ability of the killed vaccine plus
CpG to generate multi-functional, effector T cells protective
Figure 2. ALM+CpG vaccinated mice are not protected against infected sand fly challenge. Ears of AMC, ALM+CpG vaccinated (ALM), or
healed mice were exposed to the bites of 4 L.m.-infected sand flies, or needle inoculated with L.m. metacyclic promastigotes and subsequently
analyzed at the indicated time-points. (A and B) Parasite loads in individual ears 28 days following exposure to infected sand fly bite or needle
inoculation with either 10
3 L.m. parasites from culture (A) or 5610
3 L.m. parasites from infected sand flies (B). (****) p,0.0001 relative to AMC Needle
inoculated; ({{{) p=0.0002, ({{{{)p ,0.0001 relative to AMC sand fly inoculated; (111) p=0.0005, (1111)p ,0.0001 relative to ALM+CpG. (C and D)
Intracellular staining for the frequency (top number) and total number per ear (bottom number) of IFN-c
+ (C) or TNF-a
+ (D) CD4
+TcRb
+ T cells after in-
vitro re-stimulation of pooled ear-derived cells from the same groups of mice employed in 2A, with BMDC alone (DC) or DC+Ag. (E) Detection of IFN-
c by ELISA following in-vitro re-stimulation of ear derived cells with DC or DC+Ag. ({) p=0.010; ({{) 0.003,p,0.004; ({{{{)p ,0.0001 relative to DC;
(**) p=0.004; (****) p,0.0001 relative to AMC DC+Ag. (F) Frequency of TNF-a
+ and/or IFN-c
+ cells among CD3
+CD4
+-gated ear derived T cells from
the indicated groups following re-stimulation with DC or DC+Ag.
doi:10.1371/journal.ppat.1000484.g002
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present in adequate numbers and at sufficiently early time points
to protect against sand fly transmission. This point is emphasized
by the presence of similar numbers of neutrophils in both
ALM+CpG vaccinated and healed mice one week following
exposure to infected sand flies (Figure 3E), yet only healed mice
were protected. Both the rapidity of the effector response in healed
mice, as well as the fact that these cells were recruited by
Figure 3. Sand fly bite induces persistent inflammation characterized by maintenance of neutrophils at the dermal bite site. Ears of
AMC, ALM+CpG-vaccinated, and healed mice were exposed to the bites of L.m.-infected sand flies, needle inoculated with 10
3 L.m., or manipulated
by exposure to empty vials used for sand fly feeding. (A–D) Analysis of the total number of CD11b
+Ly6G
+F4/80
2 neutrophils (A and B) per ear, 6SE
(n=4–6 individual ears per group per day) or CD11b
+Ly-6C/G(Gr-1)
hi neutrophils (C and D) per ear (pooled sample) at the indicated times following
exposure to 4 L.m.-infected sand flies or needle inoculation with 10
3 sand fly (A–B) or culture (C–D) derived L.m.. CD11b
+Ly-6C/G(Gr-1)
hi cells in (C)
and (D) are 90–95% MHC II and CD11c negative, and are indicated in blue in 1E. CD11b
+Ly-6C/G(Gr-1)
int cells are 70–75% MHC II positive, 10% CD11c
positive, and are indicated in red in 1E. (**) p=0.001 and (*) 0.016,p,0.036 versus needle inoculated. (E) Representative dot plots of CD11b and Ly-
6C/G(Gr-1) expressing cells 7 days following needle inoculation or exposure to the bites of infected sand flies. (F) Visualization of LYS-eGFP
+ cells at
sites of L.major-RFP parasite deposition at the indicated times following needle inoculation or infected sand fly bite employing 2P-IVM. Individual
inoculation sites were imaged sequentially by identifying patterns of parasite deposition, hair follicles (Orange), and blood vasculature as previously
reported [34]. The left panel of images represents a low magnification view of the infection site with the boxed region indicating the area employed
for subsequent images in the time series. Scale bars=50 mM.
doi:10.1371/journal.ppat.1000484.g003
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from a ‘‘central’’ memory population, that would require antigen
encounter and several rounds of division in the DLN before
gaining effector function [43]. More likely, the rapid appearance
of these cells in the challenge site reflects a pre-existent, tissue-
seeking effector population, undergoing constant renewal by the
persistence of viable organisms in the healed mice [3,4]. Further
understanding of the effector population maintained by persistent
infection, including the role of CD8+ cells, is likely to be highly
informative to strategies of successful vaccination [44].
A critical question remains the mechanism by which neutrophil
persistence following sand fly transmission inhibits parasite
elimination in ALM+CpG vaccinated mice. Phagocyte clearance
of apoptotic neutrophils during the resolution of inflammation has
a known inhibitory effect on macrophage functions [45], and DC
functions are similarly impaired following uptake of apoptotic
neutrophils [46]. Thus, infected macrophages and DC persistently
exposed to apoptotic neutrophils at the site of sand fly bite are
likely to be refractory to activation signals, inhibiting both the
killing and APC functions of these cells. This is especially relevant
to sand fly transmission where the association between neutrophils
and macrophage/monocytes, as well as dendritic cells, is highly
localized at the sand fly bite site. Apoptosis of infected neutrophils
has been readily captured by 2P-IVM [34]. The maintenance of
neutrophils at sand fly bite sites is likely the result of conditions
leading to their protracted recruitment, as opposed to prolonga-
tion of their life span in the skin [47]. Thus, while the initial
recruitment of neutrophils may be driven primarily by tissue
injury, their continued presence is likely influenced by PSG or
salivary components, that are themselves chemotactic or that
initiate the inflammatory cascade [33].
The results reported here represent the first determination, so
far as we are aware, of the factors influencing the efficacy of
protective immunity generated by different vaccine formulations
against sand fly challenge, and may be relevant to the conditions
that modulate vaccine induced immunity to other vector borne
pathogens. Beyond emphasizing the somewhat obvious impor-
tance of using natural challenge models to evaluate experimental
vaccines against leishmaniasis, the results provide a more stringent
set of screening criteria that might be used to predict vaccine
success against fly challenge, relating to the rapid appearance of
multifunctional effector cells within the challenge site.
Figure 4. Depletion of neutrophils following sand fly bite enhances the efficacy of ALM+CpG vaccination. AMC, ALM+CpG vaccinated,
or healed mice were exposed to the bites of 4 L.m.-infected sand flies and subsequently treated with GL113 control IgG (open symbols) or NIMP-R14
neutrophil-depleting Ab (closed symbols) at 3.5, 9 and 14 days following sand fly bite. (A and B) Representative dot plot of CD11b gated, Ly6-G and
F4/80 expressing ear cells (A) and the total number of CD11b
+Ly-6G
+F4/80
2 neutrophils and CD11b
+Ly6G
2F4/80
+ macrophage/monocytes per ear
(n=4) (B), among ALM+CpG vaccinated mice 2.5 days following Ab treatment and 6 days following exposure to infected sand flies. (*) p=0.03 versus
GL113. (C) Frequency of TNF-a
+ and/or IFN-c
+ cells among CD3
+CD4
+-gated T cells after DC or DC+Ag re-stimulation of ear derived cells 15 days
following exposure to infected sand fly bites. Analysis of parasite numbers per ear (D) and lesion diameter (E) among the indicated groups 28 days
following exposure to infected sand fly bites. Each data point represents an individual ear in three pooled experiments in which animals from AMC
and ALM+CpG groups were treated with GL113 or NIMP-R14 mAb. In 4D: ({{{{)p ,0.0001 versus AMC(NIMP-R14); (**) p=0.002, (*) p=0.044 versus
ALM+CpG(GL113); (#) p=0.009, (###) p=0.0004 versus AMC(GL113). In 4E ({{{{)p ,0.0001 versus AMC(NIMP-R14); (*) p=0.011 versus
ALM+CpG(GL113).
doi:10.1371/journal.ppat.1000484.g004
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demonstrated that vaccination of BALB/c with glycoconjugates
derived from PSG diminishes disease severity following sand fly
challenge [29]. Collectively, these findings should be especially
informative for ongoing and future clinical development of
‘‘second-generation’’ Leishmania vaccines [48], and reinforce the
rationale for inclusion of molecules specific to natural transmis-
sion, such as selected components of sand fly saliva or
promastigote-secretory gel, in an anti-Leishmania vaccine [49].
Materials and Methods
Mice
Female C57BL/6 mice were obtained from Jackson Laborato-
ries. C57BL/6 LYS-eGFP knock-in mice [37] were a gift from T.
Graf (Albert Einstein University, NY) and were bred at Taconic
Laboratories through a contract with the NIAID. Mice were
maintained at a NIAID animal care facility under specific
pathogen-free conditions. All animal experiments were performed
under a study protocol approved by the NIAID Animal Care and
Use Committee.
Leishmania cell lines
All experiments were carried out using the L. major Friedlin
strain obtained from the Jordan Valley NIH/FV1 (MHOM/IL/
80/Friedlin). In some experiments, a stable transfected line of FV1
L. major promastigotes expressing a red fluorescent protein was
employed, as described previously [36]. Briefly, the DsRed gene
was amplified by PCR employing the pCMV-DsRed-Express
plasmid (BD Biosciences/Clontech) as a template and cloned into
the SpeI site of the pKSNEO Leishmania expression plasmid. FV1
promastigotes were transfected with the resulting expression
plasmid construct [pKSNEO-DsRed] and selected for growth in
the presence of 50 mg/ml Geneticin (G418) (Sigma).
Parasite preparation for needle inoculation
L. major or L. major-RFP were grown at 26uC in medium 199
supplemented with 20% heat-inactivated FCS (Gemini Bio-
Products), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM
L-glutamine, 40 mM Hepes, 0.1 mM adenine (in 50 mM Hepes),
5 mg/ml hemin (in 50% triethanolamine), and 1 mg/ml 6-biotin.
Infective-stage metacyclic promastigotes were isolated from
stationary cultures (4–6 day-old) by negative selection of non-
infective forms using peanut agglutinin [50] (PNA, Vector
Laboratories Inc). In some experiments metacyclic promastigotes
of L. major were isolated from sand flies on day 14 following
infection with L. major, as previously described [36]. Briefly,
Infected flies were killed, dissected aseptically, and the stomodeal
valve and anterior gut of each fly was transferred into Dulbecco’s
modified Eagle’s medium (DMEM). The guts were macerated
briefly using a plastic pestle, spun twice to remove the debris, and
washed once in DMEM followed by metacyclic promastigote
isolation as described above. Mice were subsequently infected with
the specified number of parasites in the ear dermis by intra-dermal
(i.d.) injection using a 29 K GA needle in a volume of 10 ml unless
specified otherwise.
Healed mice and Autoclaved Leishmania antigen (ALM)
plus CpG oligodeoxynucleotides (ODN) vaccination
Analysis of protective immunity in mice with a healed primary
lesion was carried out using animals that had been infected 16–20
weeks previously with 10
4 L. major metacyclic promastigotes in the
left hind footpad by sub-cutaneous injection using a 29 K gauge
needle in a volume of 40 ml. Autoclaved Leishmania antigen (ALM)
plus CpG oligodeoxynucleotides (ODN) vaccination was per-
formed in a manner similar to that published previously [11].
Briefly, B6 mice were injected subcutaneously in their left hind
footpad with 50 mg of clinical grade ALM, prepared from whole
cell heat-killed L. major promastigotes (WHO) plus 50 mg of CpG
ODN sequence 1826 (Coley Pharmaceutical Group), graciously
provided by Dr. P. Darrah (VRC/NIH), using a 29 K gauge
needle in a volume of 40 ml, three times, at 2 week intervals.
Infection of sand flies and transmission of L. major to
mice
Transmission of L. major parasites was performed as described
[34,36]. Briefly, 2–4 day old P. duboscqi (Mali colony) female sand
flies were infected via feeding through a chick skin membrane on
heparinized mouse blood containing L. major or L. major-RFP
amastigotes or promastigotes. After 14–15 days, individual flies
were transferred to plastic vials covered at one end with nylon
mesh. Mice were anesthetized by intraperitoneal injection of 30 ml
of ketamine/rompin (100 mg/ml). Specially designed clamps were
used to bring the mesh end of each vial into contact with the ear of
an anesthetized mouse, allowing flies inside the vial to feed on the
ear skin for a period of 2 to 3 hours in the dark. In some
experiments mice were exposed to empty vials. The number of
flies with blood meals was employed as a means of checking for
equivalent exposure to potential transmission by sand fly bite
among animals in different treatment groups. The median number
of flies with blood meals in vials with 4 flies was 2.
Processing of tissue
Ear tissue was prepared as previously described [34]. Briefly, the
ventral and dorsal sheets of needle or sand fly inoculated ears were
separated, deposited in DMEM containing 100 U/ml penicillin,
100 mg/ml streptomycin and 0.2 mg/ml Liberase CI purified
enzyme blend (Roche Diagnostic Corp.), and incubated for
2 hours at 37uC and 5% CO2. Digested ear sheets were
subsequently homogenized for 3 minutes using the Medicon/
Medimachine tissue homogenizer system (Beckton Dickinson).
Individual retromaxillary (ear) lymph nodes were removed, and
mechanically dissociated using tweezers and a syringe plunger.
Single cell suspensions of tissue homogenates were then filtered
using a 70 mm-pore size Falcon cell strainer (BD Biosciences).
Phenotypic analysis of ear derived cell populations
Mice were sacrificed and single cell suspensions from the ear
dermis were obtained as described above. Cells were incubated
without fixation with an anti-Fc-c III/II (CD16/32) receptor Ab
(2.4G2, BD Biosciences) in RPMI without phenol red (Gibco)
containing 1.0% FCS for 10’’ followed by incubation for 20’’ with
a combination of 4 or 6 of the following anti-mouse antibodies:
PE-Cy7 or APC anti-CD11b (M1/70 BD Biosciences); Per-CP
Cy5.5 anti-Gr-1(Ly6G/C) (RB6-8C5, BD Biosciences); FITC or
PE anti-Ly6G (1A8, BD Biosciences); PE anti-CD11c (HL3, BD
Biosciences); Per-CP Cy5.5 anti-CD11c (N418, BioLegend); APC
anti-F4/80 (BM8, eBioscience), FITC anti-I-A
b (AF6-120.1, BD
Biosciences); or Alexafluor-700 anti-mouse MHC II (M5/
114.15.2, eBioscience). The isotype controls employed were rat
IgG1 (R3-34) and rat IgG2b (A95-1). The data were collected and
analyzed using CELLQuest software and a FACScalibur or
FacsDIVA software and a FacsCANTO flow cytometer (BD
Biosciences). Gating of ear-derived cells was carried out as
described previously [34]. Ears were analyzed individually, or
pooled with ears from the same group, as indicated in the text.
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by flow cytometry or ELISA
Whole ear single-cell suspensions in RPMI 1640 containing 10%
FCS, 10 mM Hepes, L-glutamine, and penicillin/streptomycin,
obtained as described above, were incubated at 37uCi n5 %C O 2
for 16–18 hours in flat-bottom 48-well plates with 2.5610
5 BMDCs,
with or without 50 mg/ml freeze-thaw Leishmania antigen prepared
from L. major V1 stationary phase promastigotes, in a final volume of
1 ml.During the last5–6 hours of culture BrefeldinA (Golgiplug; BD
Biosciences) was added to block golgi transport according the
manufacturers’ instructions. Following in vitro culture, cells were
washed and stained with anti-Fc III/II (CD16/32) receptor Ab
(2.4G2) for 10 minutes in RPMI without phenol red containing 1.0%
FCS, followed by PE-Cy7 or PE-Cy5 anti-mouse CD4 (RM4-5) for
15 minutes. In some experiments cells were also stained with FITC
anti-TcR b (145-2 C11). Cells were then fixed with BD Cytofix/
Cytoperm (BD Biosciences) and stained with anti-Fc III/II (CD16/
32) receptor Ab (2.4G2) followed by a combination of the following
anti-mouse antibodies: PerCP-Cy5.5 anti-CD3 (145-2C11), FITC-,
APC-, or AlexaFluor 700 anti-IFN-g (XMG1.2), and FITC or PE
anti-TNF-a (MP6-XT22). Intracellular staining was carried out for
30 minutes on ice. All antibodies wereacquired from BD Biosciences.
For each sample, greater then or equal to 4000 CD4
+CD3
+cellswere
collected using a FACS Caliber or FACS Canto flow cytometer and
analyzed using either Cell Quest Pro or FACS Diva Software,
respectively (BD Biosciences). For measurement of IFN-c in culture
supernatants, pooled, single-cell suspensions of ear tissue as described
above wereincubated in triplicate at 37uCi n5 %CO 2for 72 hours in
96-well round bottom plates with 2.5610
5/ml BMDC with or
without freeze-thaw Leishmania antigen in a total volume of 200 ml.
Following incubation, the concentration of IFN-c in the culture
supernatant was determined by ELISA according the manufactures
instructions (eBioscience).
Estimation of parasite load and determination of lesion
size
Parasite titrations were performed as previously described [31].
Briefly, tissue homogenates were serially diluted in 96-well flat-
bottom microtiter plates containing biphasic medium, prepared
using 50 ml NNN medium containing 20% of defibrinated rabbit
blood and overlaid with 100 ml M199/S. The number of viable
parasites in each ear was determined from the highest dilution at
which promastigotes could be grown out after 7–10 days of
incubation at 26uC.
Because individual sand flies, or more then one sand fly may
deposit parasites in more than one location, sand fly bitten ears
often have more then one lesion. Total lesion diameter was
determined by measuring the diameter of individual lesions using a
caliper and in cases where there was more then one lesion per ear
the diameters were added together.
Two photon intravital skin imaging and image analysis
Two photon intravital imaging and image analysis was
performed as described previously [34]. Briefly, anesthetized mice
were imaged in the lateral recumbent position that allowed the
ventral side of the ear pinna to rest on a coverslip. A strip of
Durapore tape (3 M) was stuck to a bench top several times (to
ensure that subsequent removal would not cause undue damage)
and placed lightly over the ear pinna and affixed to the imaging
platform in order to immobilize the tissue. Care was taken to
minimize pressure on the ear.
Images were acquired using an inverted LSM 510 NLO
multiphoton microscope (Carl Zeiss Microimaging) enclosed in an
environmental chamber that was maintained at 30uC. This system
had been custom fitted with 3 external non-descanned PMT
detectors in the reflected light path. Images were acquired using
either a 206/0.8 air objective or a 256/0.8 NA water immersion
objective. Fluorescence excitation was provided by a Chamelon
XR Ti:Sapphire laser (Coherent) tuned to 920 nm for eGFP
excitation. Voxel dimensions were 0.6460.6462 mm using the
206 objective and 0.36–0.5160.36–0.5162 mm using the 256
objective.
Raw imaging data were processed with Imaris (Biplane) using a
Gaussian filter for noise reduction. All images are displayed as 2D
maximum intensity projections. Movie files of 3-dimentional
images were generated using Imaris.
Neutrophil depletion
Animals were treated with three 0.5 mg injections of a
neutrophil depleting (NIMP-R14) or control (GL113) IgG
antibody, i.p., on days 3.5, 9, and 14 following sand fly
transmission. The first dose of antibody was delayed until 3.5
days after exposure to infected sand fly bite as earlier observations
demonstrated that L.m. infection is established in macrophages at
this time [34]. Antibody treatments were spaced 5 days apart as
preliminary experiments suggested excessive administration of the
NIMP-R14 antibody, such as on successive days, led to depletion
of cell types other then neutrophils. Success and specificity of
depletions were determined as described in the text. The NIMP-
R14 hybridoma was a gift from Dr. Y. Belkaid (NIAID).
Statistical analysis
Parasite loads in the ears of mice transmitted with L. major by
infected sand fly bite do not follow a Gaussian distribution. This is
likely the result of variability in the infectious burden and feeding
behavior of individual, infected, sand flies [36]. Therefore, data sets
were compared using a nonparametric Mann Whitney test. Mann
Whitney calculations were done using Prism 4 (Graphpad Software,
Inc. San Diego, CA). In Figure 4, D and E, parasite loads and lesion
size were compared using an exact stratified Wilcoxon rank sum
test, stratified by experiment in order to allow pooling of
experiments as described in the text. The stratified Wilcoxon
calculations were done in StatXact 8 Procs (Cytel, Inc., Cambridge,
MA). Comparisons in which the data represented replicate samples
were carried out using t-tests. All p-values are two-sided.
Supporting Information
Figure S1 ALM+CpG vaccination reduces lesion size following
needle, but not infected sand fly, challenge. Ears of AMC,
ALM+CpG vaccinated (ALM), or healed mice were exposed to
the bites of 4 L.m.-infected sand flies, or needle inoculated with
10
3L.m. metacyclic promastigotes. Four weeks later, the cumula-
tive lesion diameter per ear was determined as described in
Materials and Methods. (*) p=0.04 versus AMC needle
inoculated; ({) p=0.009 versus AMC sand fly inoculated. Lesion
scores are from those mice depicted in Figure 2A.
Found at: doi:10.1371/journal.ppat.1000484.s001 (0.37 MB TIF)
Figure S2 ALM+CpG vaccination reduces lesion size following
needle challenge with 5610
3 sand fly derived L.m. metacyclic
promastigotes, but not following exposure to infected sand fly
challenge. Ears of AMC, ALM+CpG vaccinated (ALM), or healed
mice were exposed to the bites of 4 L.m.-infected sand flies, or
needle inoculated with 5610
3 sand fly derived L.m. metacyclic
promastigotes. At 4 weeks post-challenge, the cumulative lesion
diameter per ear was determined as described in materials and
methods. (*) p=0.006, (****) p,0.0001 versus AMC needle
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scores are from those ears depicted in Figure 2B.
Found at: doi:10.1371/journal.ppat.1000484.s002 (0.39 MB TIF)
Figure S3 Kinetic analysis of lymphocyte recruitment to sites of
needle or sand fly inoculation of L. major. Single cell suspensions of
individual ears (n=8–10) from the groups depicted in Figure 2A
and Figure 3C–E, following exposure to the bites of 4 L.m.-infected
sand flies (white square, Age Matched Control (AMC); white
circle, Autoclaved Leishmania major (ALM)+CpG; white triangle,
Healed) or needle inoculated with 10
3L.m. metacyclic promasti-
gotes (black square, AMC; black circle, ALM+CpG) were pooled,
mixed 1:1 with trypan blue, and the number of live lymphocytes
per ear was determined by trypan blue exclusion and morphology.
Found at: doi:10.1371/journal.ppat.1000484.s003 (0.45 MB TIF)
Video S1 Formation of neutrophil ‘‘plugs’’ and L. major deposition
at acute time points following infected sand fly bite. Two-dimentional
(XY) image series through the Z-plane from a LYS-eGFP mouse
2 hours following exposure of the ventral ear pinna to the bites of
L.m.-RFP infected sand flies. Movie is derived from the 2 hour
infected sand fly bite image depicted in Figure 3F. The firstslice is the
ventral ear surface. Playback speed is 4 Z-slices per second.
Dimensions of the imaging field are 369(Y)6369(Y)676(Z) mm.
Found at: doi:10.1371/journal.ppat.1000484.s004 (0.89 MB
MOV)
Video S2 Neutrophil recruitment to a site of parasite deposition
at acute time points following needle inoculation of L. major. Two-
dimentional (XY) image series through the Z-plane from a LYS-
eGFP mouse 2 hours following intra-dermal needle inoculation of
the ventral ear pinna with 500 L.m.-RFP metacyclic promastigotes
in 2 ml. Movie is derived from the 2 hour needle inoculated image
depicted in Figure 3F. The first slice is the ventral ear surface.
Playback speed is 4 Z-slices per second. Dimensions of the imaging
field are 521(Y)6521(Y)682 (Z) mm.
Found at: doi:10.1371/journal.ppat.1000484.s005 (1.19 MB
MOV)
Video S3 Formation of neutrophil ‘‘plugs’’ and L. major
deposition following infected sand fly bite. Second example of a
2-dimentional (XY) image series through the Z-plane from a LYS-
eGFP mouse 2 hours following exposure of the ventral ear pinna
to the bites of L.m.-RFP infected sand flies. The first slice is the
ventral ear surface. Playback speed is 2 Z-slices per second.
Dimensions of the imaging field are 280(X)6369(Y)688(Z) mm.
Found at: doi:10.1371/journal.ppat.1000484.s006 (0.69 MB
MOV)
Video S4 Neutrophil recruitment to a site of parasite deposition
by sand fly inoculation. Two-dimentional (XY) image series
through the Z-plane from a LYS-eGFP mouse 8 days following
exposure of the ventral ear pinna to the bites of L.m.-RFP infected
sand flies. Movie is derived from the day 8–12 infected sand fly
bite image depicted in Figure 3F. The first slice is the ventral ear
surface. Playback speed is 4 Z-slices per second. Dimensions of the
imaging field are 369(Y)6369(Y)676(Z) mm.
Found at: doi:10.1371/journal.ppat.1000484.s007 (0.72 MB
MOV)
Video S5 Neutrophil recruitment to a site of parasite deposition
by needle inoculation. Two-dimentional (XY) image series
through the Z-plane from a LYS-eGFP mouse 12 days following
needle inoculation of the ventral ear pinna with 500 L.m.-RFP
metacyclic promastogites in 2 ml. Movie is derived from the day 8–
12 needle inoculated image depicted in Figure 3F. The first slice is
the ventral ear surface. Playback speed is 4 Z-slices per second.
Dimensions of the imaging field are 521(Y)6521(Y)682 (Z) mm.
Found at: doi:10.1371/journal.ppat.1000484.s008 (1.03 MB
MOV)
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